Category Archives: Biotechnology

The 62 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AKROs 62 overall rating means the stock scores better than 62 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Akero Therapeutics Inc (AKRO) stock has gained 3.4% while the S&P 500 is lower by -0.22% as of 3:14 PM on Tuesday, Dec 22. AKRO has gained $0.87 from the previous closing price of $25.62 on volume of 255,146 shares. Over the past year the S&P 500 is higher by 14.35% while AKRO has gained 21.96%. AKRO lost -$2.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Akero Therapeutics Inc (AKRO) Stock.

More here:
Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? - InvestorsObserver

A rating of 64 puts Spectrum Pharmaceuticals, Inc. (SPPI) near the middle of the Biotechnology industry according to InvestorsObserver. Spectrum Pharmaceuticals, Inc.'s score of 64 means it scores higher than 64% of stocks in the industry. Spectrum Pharmaceuticals, Inc. also received an overall rating of 54, putting it above 54% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spectrum Pharmaceuticals, Inc. (SPPI) stock is lower by -9.18% while the S&P 500 is higher by 0.46% as of 9:56 AM on Wednesday, Dec 23. SPPI is down -$0.39 from the previous closing price of $4.25 on volume of 501,103 shares. Over the past year the S&P 500 is higher by 14.92% while SPPI is down -55.89%. SPPI lost -$1.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spectrum Pharmaceuticals, Inc. (SPPI) Stock.

Read the original:
Is Spectrum Pharmaceuticals, Inc. (SPPI) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Voyager Therapeutics Inc (VYGR) is around the bottom of the Biotechnology industry according to InvestorsObserver. VYGR received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Voyager Therapeutics Inc also achieved a score of 22 in the Biotechnology industry, putting it above 22 percent of Biotechnology stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Voyager Therapeutics Inc (VYGR) stock is lower by -10.52% while the S&P 500 has gained 0.46% as of 9:56 AM on Wednesday, Dec 23. VYGR has fallen -$0.95 from the previous closing price of $9.03 on volume of 156,970 shares. Over the past year the S&P 500 has risen 14.92% while VYGR has fallen -46.06%. VYGR earned $1.04 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.77.

Click Here to get the full Stock Score Report on Voyager Therapeutics Inc (VYGR) Stock.

Go here to read the rest:
Is Voyager Therapeutics Inc (VYGR) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. As with many other companies Medigen Biotechnology Corp. (GTSM:3176) makes use of debt. But is this debt a concern to shareholders?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.

View our latest analysis for Medigen Biotechnology

The image below, which you can click on for greater detail, shows that at September 2020 Medigen Biotechnology had debt of NT$1.37b, up from NT$1.17b in one year. However, because it has a cash reserve of NT$887.8m, its net debt is less, at about NT$479.5m.

Zooming in on the latest balance sheet data, we can see that Medigen Biotechnology had liabilities of NT$976.6m due within 12 months and liabilities of NT$1.17b due beyond that. On the other hand, it had cash of NT$887.8m and NT$123.1m worth of receivables due within a year. So its liabilities outweigh the sum of its cash and (near-term) receivables by NT$1.13b.

Since publicly traded Medigen Biotechnology shares are worth a total of NT$8.17b, it seems unlikely that this level of liabilities would be a major threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. When analysing debt levels, the balance sheet is the obvious place to start. But you can't view debt in total isolation; since Medigen Biotechnology will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

Over 12 months, Medigen Biotechnology reported revenue of NT$595m, which is a gain of 26%, although it did not report any earnings before interest and tax. With any luck the company will be able to grow its way to profitability.

Despite the top line growth, Medigen Biotechnology still had an earnings before interest and tax (EBIT) loss over the last year. Its EBIT loss was a whopping NT$857m. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. Quite frankly we think the balance sheet is far from match-fit, although it could be improved with time. However, it doesn't help that it burned through NT$776m of cash over the last year. So in short it's a really risky stock. When we look at a riskier company, we like to check how their profits (or losses) are trending over time. Today, we're providing readers this interactive graph showing how Medigen Biotechnology's profit, revenue, and operating cashflow have changed over the last few years.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

PromotedIf you decide to trade Medigen Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

The rest is here:
Does Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet? - Simply Wall St

Baltimore,Maryland The U.S. Attorneys Office for the District of Maryland has seized mordernatx.com and regeneronmedicals.com, which purported to be the websites of actual biotechnology companies developing treatments for the COVID-19 virus, but instead appears to have been used to collect the personal information of individuals visiting the sites, in order to use the information for nefarious purposes, including fraud, phishing attacks, and/or deployment of malware. Individuals visiting those sites now will see a message that the site has been seized by the federal government and be redirected to another site for additional information.

The seizure of the domain names was announced by United States Attorney for the District of Maryland Robert K. Hur and Special Agent in Charge John Eisert of Homeland Security Investigations Baltimore.

The U.S. Attorneys Office and our law enforcement partners are committed to bringing to justice the criminals that try to take advantage of this global pandemic to line their pockets at the expense of the most vulnerable, said U.S. Attorney Robert K. Hur. I urge citizens to remain vigilant. Dont provide personal information or click on websites or links contained in unsolicited e-mails. Dont become a victim.

These individuals took advantage of fear during the global pandemic and attempted to steal personal information for nefarious purposes, said HSI Baltimore Special Agent in Charge John Eisert. From the cyber realm to counterfeit medication to financial crime, Homeland Security Investigations is committed to detecting, investigating, and disrupting all types of fraud related to the COVID-19 pandemic.

According to the affidavits filed in support of these seizures, these investigations began in early December 2020, after corporate security for one of the companies located the spoof website and contacted HSIs Intellectual Property Rights Center (IPRC) and the HSI Cyber Crimes Center (C3). The other website was identified during an ongoing HSI C3 operation targeting malicious websites. The cases were referred to HSI Baltimore for investigation.

Specifically, on December 10, 2020, the Global Head of Corporate Security for a biotechnology company headquartered in Cambridge, Massachusetts, which has developed a COVID-19 vaccine that is awaiting approval by the U.S. Food and Drug Administration (FDA), contacted HSI IPRC and C3 by e-mail to report that the companys Cybersecurity Team had detected the domain name mordernatx.com, a fraudulent replication of the companys website. A review of that websites online content displayed the name and trademarked logos for the biotechnology company. As detailed in the affidavit, the logos, markings, colors, and text of the mordernatx.com webpage showed no substantive differences from the genuine company websites landing page, other than the fact that the fraudulent website had a slight misspelling of the companys name. However, individuals who clicked on the Contact Us tab, were redirected to an entry form requesting information such as name, company/institution, title, phone, e-mail, and comments/questions. Additional investigation revealed that the mordernatx.com domain name was registered on about December 8, 2020, through a company headquartered in Kuala Lumpur, Malaysia, with no personal information for the registrar listed.

The second domain name seized, regeneronmedicals.com, was identified on December 9, 2020, during an ongoing HSI C3 investigation targeting malicious websites. Investigators found that the subject domain name contained the name and trademarked logos of, and was visually similar to, the webpage of a biotechnology company headquartered in Westchester County, New York, which was granted an emergency use authorization by the FDA for an antibody cocktail used to treat COVID-19 in high-risk patients with mild to moderate COVID-19. Further investigation revealed that the subject domain name contained two e-mail addresses and a telephone number not found on the official company website. The phone number appeared to be a Voice over IP (VOIP) number. In addition, the Contact Us page on the regeneronmedicals.com site directed Healthcare professionals, patients or caregivers requesting specific product information, reporting an adverse event or reporting a product complaint to contact the Medical Department at the VOIP number. The same Contact Us tab also provided a link to submit medical inquiries which directed users to a page that was different from the corresponding page on the authentic website. Investigators also found that the subject domain name was registered on December 6, 2020, and lists the registrant as an individual residing in Onitsha Anambra, Nigeria.

By seizing these sites, the government has prevented third parties from acquiring the names and using them to commit additional crimes, as well as prevented third parties from continuing to access the sites in their present form.

Federal law enforcement agencies are united in our efforts to fight against COVID-19 fraud. HSI has identifiedtipsto recognize and report COVID-19 fraud. If you believe you are a victim of a fraud or attempted fraud involving COVID-19, you may also call the National Center for Disaster Fraud Hotline at 1-866-720-5721 or for more information e-mail justice.gov/coronavirus.

United States Attorney Robert K. Hur commended HSI for its work in these investigations. Mr. Hur thanked Assistant U.S. Attorneys Sean Delaney, Aaron S.J. Zelinsky, and Thomas M. Sullivan, who are handling these cases.

Like Loading...

Related

Go here to see the original:
Maryland US Attorney's Office Seizes Two Domain Names Purporting to be Websites of Biotechnology Companies Developing Treatments for Covid-19 - The...

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Global Gynecology Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Gynecology Partnering 2010-2020: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Global Gynecology Partnering 2010 to 2020 includes:

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Gynecology dealmaking2.1. Introduction2.2. Gynecology partnering over the years2.3. Gynecology partnering by deal type2.4. Gynecology partnering by industry sector2.5. Gynecology partnering by stage of development2.6. Gynecology partnering by technology type2.7. Gynecology partnering by therapeutic indication

Chapter 3 Financial deal terms for Gynecology partnering3.1. Introduction3.2. Disclosed financials terms for Gynecology partnering3.3. Gynecology partnering headline values3.4. Gynecology deal upfront payments3.5. Gynecology deal milestone payments3.6. Gynecology royalty rates

Chapter 4 Leading Gynecology deals and dealmakers4.1. Introduction4.2. Most active in Gynecology partnering4.3. List of most active dealmakers in Gynecology4.4. Top Gynecology deals by value

Chapter 5 Gynecology contract document directory5.1. Introduction5.2. Gynecology partnering deals where contract document available

Chapter 6 Gynecology dealmaking by therapeutic target6.1. Introduction6.2. Deals by Gynecology therapeutic target

AppendicesAppendix 1 Directory of Gynecology deals by company A-Z 2010 to 2020Appendix 2 Directory of Gynecology deals by deal type 2010 to 2020Appendix 3 Directory of Gynecology deals by stage of development 2010 to 2020Appendix 4 Directory of Gynecology deals by technology type 2010 to 2020

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9ex5qc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:
Global Gynecology Partnering Report 2020: Access Deals Signed Between the World's Leading Pharmaceutical and Biotechnology Companies Since 2010 -...

The Pharmaceutical And Biotechnology Machines Marketreport enlists essential and realistic data with regards to the market situation. The current situation of the Pharmaceutical And Biotechnology Machines market, alongside its preceding overall performance as properly as future scope are included in the report. It demonstrates a quick summary of industry facts and the key nomenclature of the market. The report has highlights, regularly occurring performers, from the global market together with their contribution to the market to decide their growth inside the estimated time.

Furthermore, The report covers key strategic points regarding developments in the market which include acquisitions & mergers, agreements, partnerships, new type launches, research & development, collaborations & joint ventures, regional growth of predominant contributors concerned in the Pharmaceutical And Biotechnology Machines market on a global and regional basis.

Get Sample Report + All Related Graphs & Charts: https://www.stratagemmarketinsights.com/sample/19841

It Furnishes detailed information on the factors that will restrain the growth of Pharmaceutical And Biotechnology Machines manufacturers: Air Liquide, Linde Healthcare, Praxair, Air Products, Taiyo Nippon Sanso, Matheson Gas, Atlas Copco AB, Messer Group, SOL Group, Norco, Sicgil Limited, Shenzhen Gaofa, Shenwei Medical, Beijing Orient, Nanning Lantian

Pharmaceutical And Biotechnology Machines Market COVID-19 Impact Analysis:

As the world is still dealing with the COVID-19 situation, many of the countries have slowly started to revive their economic situation by starting their trade and businesses. There has been an enormous loss in these few months both in terms of economy and human lives. As the WHO has already suggested that there are very less chances that the virus will completely go, hence we will have started living with it. Many of the drug companies are getting a positive response to their COVID-19 vaccines, but there is still time for their availability in the global market.

Research Methodology:

The process of market research at SMI is iterative in nature and generally follows the following path. Information from secondary is used to construct records models, in addition, the consequences got from data models are validated from essential participants. Then cycle repeats where, in accordance with inputs from important participants, additional secondary research is completed and new information is once more integrated into the data model. The process continues until the favored degree of facts is no longer generated.

To calculate the Pharmaceutical And Biotechnology Machines market size, the report considers the revenue generated from the sales of the market providers. The revenue generated from the sales of the market is calculated through essential and secondary research. The key players working in the market throughout the globe are recognized via secondary research and a corresponding detailed analysis of the top vendors in the market is done. The market size calculation additionally consists of clinical trial phase segmentation that decided the usage of secondary sources and verified thru primary sources.

The report covers exhaustive analysis on:

Regional analysis includes:

Report Highlights:

Key Question and Answers in the Study:

Get assured Discount on this Report (UsePrompocodeCHRISTMAS25):https://www.stratagemmarketinsights.com/discount/19841

[**Note: To avail of this offer Specify this Promo code in precise requirement.]

Contact Us:

Mr. ShahStratagem Market InsightsTel:USA +1-415-871-0703JAPAN +81-50-5539-1737UK +44-203-289-4040Email: [emailprotected]

Explore BySJ

Read the original post:
Pharmaceutical And Biotechnology Machines Market Thriving Impulsive Hike With Key Players - LionLowdown

TipRanks

Semiconductors are one of the modern worlds essential industries, making possible so much of what we rely on or take for granted: internet access, high-speed computers with high-speed memory, even the thermostats that control our air conditioning there isnt much, tech-wise, that doesnt use semiconductor chips.With the end of 2020 in sight, its time for the annual ritual of evaluating the equities for the New Year. Wells Fargo analyst Aaron Rakers has cast his eye on the chip industry, tagging several companies as likely gainers next year.The analyst sees several factors combining to boost demand for chips in 2021, including cloud demand, new gaming consoles, and a market resolution to the future of the PC segment. Overall, however, Rakers expects that memory chips and 5G enabled chips will emerge as the drivers of the industry next year. The analyst expects that semiconductor companies, as a group, will see between 10% and 12% growth over the next 12 months.Thats an industry-wide average, however. According to Raker, some chip companies will show significantly higher growth, on the order of 30% to 40% in year ahead. We can look at those companies, along with the latest TipRanks data, to find out what makes these particular chip makers so compelling.Micron Technology (MU)Among the leading chip makers, Micron has staked out a position in the memory segment. The company has seen its market cap expand to $78 billion this year, as shares have appreciated 32% year-to-date. The surge comes on a product line heaving on computer data storage, DRAM, and flash storage.Look back at 2020, Micron has seen revenues increase each quarter, from $4.8 billion in Q1 to $5.4 billion in Q2 to $6.1 billion in Q3. Earnings came in at 87 cents per share, up from 71 cents in Q2 and 36 cents in Q1.The calendar third quarter was Microns 4QFY20, and the full fiscal year showed a decline due attributed to the COVID pandemic. Revenue came in at $21.44 billion, down 8.4% year-over-year, and operating cash flow fell to $8.31 billion from $13.19 billion in FY19. During this past quarter, Microns 1QFY21, the company announced the release of the worlds first 176-layer 3D NAND chip. The new chip promises higher density and faster performance in flash memory, and the architecture is described as a radical breakthrough. The layer count is 40% higher than competing chips.Looking ahead, Micron has updated its F1Q21 guidance, predicting total revenue of $5.7 billion to $5.75 billion. This is a 10% increase from the previous guidance.Wells Fargo's Aaron Rakers calls Micron his top semiconductor idea for 2021. He points out a deepening positive view on the memory, and in particular the DRAM industry. DRAM accounts for approximately two-thirds of Microns revenue and over 80% of the companys bottom-line profits. In addition, Rakers notes Microns technology execution 1Znm DRAM leadership; recently outlined 1nm ramp into 2021, as well as Microns move to 176-Layer 2nd -gen Replacement Gate 3D NAND to drive improved cost curve. We would also highlight Microns execution on graphics memory (e.g., GDDR6X), Multi-Chip Packages (MCPs), and High-Bandwidth Memory (e.g., HBME2) as positives.In line with these comments, Rakers rates Micron shares a Buy, along with a $100 price target. This figure suggests room for 41% growth in 2021. (To watch Rakers track record, click here)Micron has 24 recent reviews on record, breaking down to 19 Buys, 4 Holds, and 1 Sell, and giving the stock a Strong Buy from the analyst consensus. Shares are priced at $70.96, and recent appreciation has pushed them almost to the $74.30 average price target. But as Rakers outlook suggests, there may be more than just 4.5% upside available here. (See MU stock analysis on TipRanks)Advanced Micro Devices (AMD)With $6.5 billion in total sales last year, and a market cap of $110.7 billion, AMD is a giant company but it doesnt even crack the top five of the worlds largest chip makers. Still, AMD has a solid position in the industry, and its x86 processors provide stiff competition for market-leading Intel (INTC). AMD shares have shown solid growth this year, and are up 101% as 2020 comes to a close.The share growth rides on the back of steady revenue gains since the corona crisis peaked in Q1. AMDs Q3 top line came in at $2.8 billion, up 55% from the $1.8 billion recorded in the year-ago quarter and beating the forecast by 10%. Earnings, at 37 cents per share, were up 220% year-over-year. The company credited the growth to solid results in the PC, gaming, and data center product lines, and boasted that it was the fourth consecutive quarter with >25% yoy revenue growth.AMD announced last month a new product for the scientific research market, the Instinct MI100 accelerator. The new chip is billed as the worlds fasted HPC GPU, and the first such x86 server to exceed 10 teraflops performance.Covering AMD for Wells Fargo, Rakers wrote: We remain positive on AMDs competitive positioning for continued sustained gradual share gains in PCs We also believe AMDs deepening data center GPU strategy with new Instinct MI100 GPUs and the release of RoCM 4.0 software platform could become increasingly visible as we move through 2021. AMDs roadmap execution would remain an important focus 7nm+ Ryzen 4000-series, new RDNA Radeon Instinct data center GPUs (MI100 / MI120), and the 3 rd -gen 7nm+ EPYC Milan CPUsRakers stance supports his Buy rating, and his $120 price target implies a 30% one-year upside to the stock.The Moderate Buy analyst consensus view on AMD reflects some residual Wall Street caution. The stocks 20 recent reviews include 13 Buys, 6 Holds, and 1 Sell. AMD shares are selling for $91.64, and like Micron, their recent appreciation has closed the gap with the $94.71 average price target. (See AMD stock analysis on TipRanks)Western Digital Corporation (WDC)Closing out the Wells Fargo picks on this list is Western Digital, a designer and manufacturer of memory systems. The companys products include hard disk drives, solid state drives, data center platforms, embedded flash drives, and portable storage including memory cards and USB thumb drives. WDC has had a tough year in 2020, with shares down 19% year-to-date. Still, the stock has seen gains in November and December, on the heels of what was seen as a strong fiscal 1Q21 report.That earnings report showed $3.9 billion in revenue, which was down 3% year-over-year, but the EPS net loss, at 19 cents, was a tremendous yoy improvement from the 93-cent net loss in the year-ago quarter. The earnings improvement, which beat the forecast by 20%, was key for investors, and the stock is up 30% since the quarterly report. The company also generated a solid cash flow in the quarter, with cash from operations growing 111% sequentially.Wells Fargos Rakers acknowledges WDCs difficulties in 2020, but even so, he believes that this is a stock which is worth the risk.Western Digital has been our toughest constructive call of 2020 and while we believe calling a bottom in NAND Flash (mid/2H2021?) remains difficult and WDs execution in enterprise SSDs will remain choppy, our SOTP analysis leaves us to continue to believe that shares present a compelling risk / reward. We continue to believe that Western Digital can drive to a ~$7/sh.+ mid-cycle EPS story; however, we continue to think a key driver of this fundamental upside will not only be a recovery in the NAND Flash business, coupled with WDs ability to see improved execution in enterprise SSDs, but also a continued view that WDs HDD gross margin can return to a sustainable 30%+ level, Rakers opined.To this end, Rakers rates WDC a Buy along with a $65 price target. Should the target be met, investors could pocket gains of 29% over the next months Where does the rest of the Street side on this computer-storage maker? It appears mostly bullish, as TipRanks analytics demonstrate WDC as a Buy. Out of 11 analysts tracked in the last 3 months, 7 are bullish, while 4 remain sidelined. With a return potential of 9%, the stocks consensus target price stands at $54.44. (See WDC stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Excerpt from:
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock? - Yahoo Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. Indeed, Vir Biotechnology (NASDAQ:VIR) stock is up 147% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

Given its strong share price performance, we think it's worthwhile for Vir Biotechnology shareholders to consider whether its cash burn is concerning. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

See our latest analysis for Vir Biotechnology

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In September 2020, Vir Biotechnology had US$827m in cash, and was debt-free. Looking at the last year, the company burnt through US$153m. So it had a cash runway of about 5.4 years from September 2020. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. The image below shows how its cash balance has been changing over the last few years.

Some investors might find it troubling that Vir Biotechnology is actually increasing its cash burn, which is up 18% in the last year. Given that it boosted operating revenue by a stand-out 639% in the same period, we think management are simply more focussed on growth than preserving cash. It may well be that it has some excellent opportunities to invest in growth. We think it is growing rather well, upon reflection. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

We are certainly impressed with the progress Vir Biotechnology has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Vir Biotechnology's cash burn of US$153m is about 3.9% of its US$3.9b market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

It may already be apparent to you that we're relatively comfortable with the way Vir Biotechnology is burning through its cash. For example, we think its revenue growth suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, we conducted an in-depth investigation of the company, and identified 4 warning signs for Vir Biotechnology (1 is concerning!) that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

PromotedIf you decide to trade Vir Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Read more from the original source:
We're Interested To See How Vir Biotechnology (NASDAQ:VIR) Uses Its Cash Hoard To Grow - Simply Wall St

ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ)on this weeks ETF of the Week podcast with Chuck Jaffe on the MoneyLife Show.

IBBJ covers companies around the globe that are focused on various areas within the biotech or pharmaceuticals space. Included companies are those involved in genomics, DNA technology, genetic engineering, and molecular biology, as well as pharmaceutical manufacturers of prescription or over-the-counter drugs. Its emphasis on pharmaceuticals makes IBBJ to differ from some peer funds and its segment benchmark. The underlying index concentrates its exposure to approximately 200 small-cap stocks that are exclusively listed on the NASDAQ Stock Market. Stocks selected must meet certain size and liquidity requirements. The index is market-cap weighted with an 8% single security cap for five securities, and the excess is allocated proportionally across the rest. The indexs rebalance, and reconstitution occurs semi-annually.

Targeted exposure to junior disruptors in the biotechnology space as drugmakers focus on specialized or targeted drug applications. Theplay on innovations comes out of smaller companies. That also means theres a play on potential increased merger & acquisition activity. As big blockbuster drugs see patents expire, many big-named companies are now looking for merger/acquisition targets through smaller specialty drugmakers.

Junior biotech companies, with a market capitalization that is less than $5 billion, have the potential advantage of a Food and Drug Administration more receptive to new cutting-edge and rare-disease therapies.They are possibly also strengthened by increased patient lobbying and a greater willingness by insurers to pay for treatments.Combined with the potential for mergers-and-acquisitions and the U.S. governments recent gigantic Covid-19 aid to small and mid-sized companies, small-caps seemed likely to lead the domestic recovery.

As far as government support, theDovish Federal Reserve provides cheap loans for small businesses. TheU.S. governments gigantic Covid-19 aid package for small- and mid-sized companies was also there. Plus, theU.S. government has been throwing out billions of dollars for Operation Warp Speed to fund Covid-19 vaccine research.

The value of the global pharmaceutical market rose from about $390 billion in 2001 to about $1.25 trillion at the end of 2019. Research and development expenditures in this industry grew to $179 billion by 2018 from $129 billion in 2010. Theindustry has experienced a 3% compound annual growth rate since 2014.

Whether for cancer research, or a vaccine or treatment for Covid-19, the strong demand side continues to combine with government regulation and policies prioritizing these sectors.In uncertain and unpredictable times, biotechnology benchmarks have been known to beat the wider market.

View post:
ETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ) - ETF Trends